Osivax is a Clinical-stage biotech company
Osivax has raised €50M across 3 funding rounds from 4 investors, most recently a Series B round in Mar 2025. Based in Lyon, France; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2025-03-04 | Series B | €9.5M | Meiji Seika Pharma | View deal → |
| 2020-07-09 | Other | €33M | Bpifrance,European Innovation Council | View deal → |
| 2019-07-01 | Series A | €8.0M | Meusinvest (Noshaq) | View deal → |
